$Cellectis(CLLS.US)$ NEWS Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs Cellectis presents novel TALEN editing processes enabling highly efficient gene correction and gene insertion in HSPCs, showcasing the potential and versatility of the technology for gene therapy. The company will present first data exploring these processes at ASGCT. The editing approaches could revolutionize the treatment of metabolic and neurologica...
$Cellectis(CLLS.US)$ NEWS Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs Cellectis (NASDAQ: CLLS) announces a breakthrough in gene-editing therapy with the publication of a new research paper. The study demonstrates the potential of TALEN-mediated intron editing in HSPCs for targeted transgene expression, offering new treatment possibilities for metabolic and neurological diseases.
$Cellectis(CLLS.US)$Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs 3 MINUTES AGO, 4:30 PM EDT VIA GLOBENEWSWIRE NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that...
Jean Pierre Garnier, Cellectis Chairman, thanked shareholders for supporting the Additional Investment and welcomed Mr. Dunoyer and Dr. Rivers to the board, praising their pharma industry experience.
$Cellectis(CLLS.US)$reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.42) by 14.29 percent. This is a 37.93 percent increase over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $1.64 million which missed the analyst consensus estimate of $3.58 million by 54.08 percent. This is a 14.42 percent decrease over sales of $1.92 million the same period last year.
Cellectis股票討論區
NEWS
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
Cellectis presents novel TALEN editing processes enabling highly efficient gene correction and gene insertion in HSPCs, showcasing the potential and versatility of the technology for gene therapy. The company will present first data exploring these processes at ASGCT. The editing approaches could revolutionize the treatment of metabolic and neurologica...
NEWS
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Cellectis (NASDAQ: CLLS) announces a breakthrough in gene-editing therapy with the publication of a new research paper. The study demonstrates the potential of TALEN-mediated intron editing in HSPCs for targeted transgene expression, offering new treatment possibilities for metabolic and neurological diseases.
3 MINUTES AGO, 4:30 PM EDT
VIA GLOBENEWSWIRE
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that...
News
I'm Looking At This Stock For Huge Upside Potential | Cellectis CLLS Stock
Earnings
暫無評論